The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is monitoring the COVID-19 pandemic very closely and sharing evidence-based and expert validated information to the global primary immunodeficiency (PID) patients’ community and to our stakeholders. One of our most valuable tools is the COVID-19 and PID FAQs web page. This page is the result of questions submitted by our National Member Organisations (NMOs) in the different world regions and the answers are provided by our expert guests on Webchats. 

IPOPI’s COVID-19 and PID Webchats are held periodically to help address concerns, tackle disinformation and clear up any doubts from our members about COVID-19 and primary immunodeficiencies (PIDs). Our NMOs look up to IPOPI as their international representative to provide accurate information so they can, in turn, provide more answers to their membership.

Each Webchat addresses issues related to the pandemic, such as, prevention, a potential vaccine, the nursing perspective, lessons learnt from different regions/countries, supply of immunoglobulin (lifesaving therapy with no other alternative for most PID patients) during and after the pandemic, how countries with limited resources address this healthcare crisis, among many others. IPOPI invites leading PID experts from across the globe to discuss the questions raised by the NMOs and is keeping an updated COVID-19 and PIDs FAQs page.

IPOPI has also taken part in similar regional calls and our Board Members remain very active in the regions of their responsibility.

Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic. IPOPI has been engaging on several fronts to fast track the publication of statements and open letters on the matter and has participated in international efforts to collect data on COVID-19 in PIDs. This page aggregates all IPOPI’s efforts and selected external statements.